Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk Targets Japan Self-Pay Market as Only 14,000 Access Obesity Drugs
07:23am, Thursday, 19'th Mar 2026
Novo Nordisk (NVO) is testing a new route to unlock obesity drug demand in Japan, where strict reimbursement rules have slowed uptake despite rising global inte
1 Reason I'm Never Selling Novo Nordisk Stock
07:00am, Thursday, 19'th Mar 2026
Novo Nordisk has been a leader in its core market for decades. This grants the pharmaceutical giant several advantages.
Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India
05:22am, Thursday, 19'th Mar 2026
India's market for diabetes and weight-loss drugs is set for a shake-up as Danish drugmaker Novo Nordisk's patent on semaglutide expires this week, triggering a wave of cheaper generics from local
Novo Nordisk (NVO) Declines More Than Market: Some Information for Investors
06:46pm, Wednesday, 18'th Mar 2026
Novo Nordisk (NVO) closed the most recent trading day at $37.45, moving 2.55% from the previous trading session.
TrumpRx lists many medicines at prices higher than paid in UK
02:23pm, Wednesday, 18'th Mar 2026
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those
Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says
02:06pm, Wednesday, 18'th Mar 2026
Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients with Type 2 diabetes.
The Best Healthcare Stocks to Buy With $50 Right Now
08:30am, Wednesday, 18'th Mar 2026
Pfizer and Novo Nordisk look cheap in more ways than one. Pipeline progress could help improve their financial results.
Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise Move
07:00pm, Tuesday, 17'th Mar 2026
Hims & Hers' stock is up after ending its lawsuit with Novo Nordisk. The deal shows that industry power lies with the drugmakers.
This Promising GLP-1 Drug Could Give Novo Nordisk Investors Renewed Hope for the Stock
10:30am, Tuesday, 17'th Mar 2026
Novo Nordisk recently announced promising trial results for one of its GLP-1 drugs in development.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
10:01am, Tuesday, 17'th Mar 2026
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Rival GLP-1 pill matches Wegovy weight loss data, adding to competitive pressure on Novo Nordisk
09:33am, Tuesday, 17'th Mar 2026
Citi has kept its 'neutral' rating on Novo Nordisk (NYSE:NVO) after a rival company released clinical data showing its oral GLP-1 drug delivered weight loss broadly comparable to Novo's own obesity pi
Rival GLP-1 pill matches Wegovy weight loss data, adding to competitive pressure on Novo Nordisk
09:03am, Tuesday, 17'th Mar 2026
Citi has kept its 'neutral' rating on Novo Nordisk (NYSE:NVO) after a rival company released clinical data showing its oral GLP-1 drug delivered weight loss...
Novo Nordisk A/S Investigated by the Portnoy Law Firm
09:00am, Tuesday, 17'th Mar 2026
LOS ANGELES, March 17, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Novo Nordisk A/S (“Novo Nordisk" or the "Company") (NYSE:NVO) investors that the firm has initiated an investigation into
Novo Nordisk: Buy Hand Over Fist While Others Panic
08:13am, Tuesday, 17'th Mar 2026
Novo Nordisk remains a Strong Buy despite a 20% stock decline following disappointing CagriSema trial results versus Eli Lilly's tirzepatide. NVO's valuation is compelling, with a P/E of 10.42 and FCF
Abacus Global Management to attend Roth Conference
05:44am, Tuesday, 17'th Mar 2026
Abacus Global Management (NYSE:ABX) announced that it will participate in the 38th Annual Roth Conference on March 23 to 24 in Laguna Niguel, California....
